<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15175">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00196313</url>
  </required_header>
  <id_info>
    <org_study_id>DR-PSE-306</org_study_id>
    <nct_id>NCT00196313</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain</brief_title>
  <official_title>A Multicenter Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval to Placebo for the Treatment of Cyclic Pelvic Pain in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duramed Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the effects of treatment with Seasonique an
      extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the
      typical hormone-free interval. Patients will receive 13 weeks of treatment with the option
      to extend blinded therapy for an additional 13 weeks. The overall study duration will be 6-9
      months. Patients will be required to record menstrual pain in a daily diary.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Change in Average Severity for Abdominal/Pelvic Pain</measure>
    <time_frame>Baseline to end of 13-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the sum of pain scores divided by the total number of days in which the subject experienced abdominal/pelvic pain, from baseline to Week 13 The severity of the pain was assessed using a 4-points scale (0 = &quot;None&quot;, 1 = &quot;Mild&quot;, 2 = &quot;Moderate&quot;, 3 = &quot;Severe&quot;)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Severity of Abdominal/Pelvic Pain</measure>
    <time_frame>Baseline to end of Week 13</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum pain severity score was calculated by identifying each subject's maximum recorded pain severity from baseline to end of Week 13.
The severity of the pain was assessed using a 4-points scale (0 = &quot;None&quot;, 1 = &quot;Mild&quot;, 2 = &quot;Moderate&quot;, 3 = &quot;Severe&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Menstrual Bleeding and /or Spotting</measure>
    <time_frame>Baseline to end of Week 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Missed From School/Work or Other Activities</measure>
    <time_frame>13-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic Use</measure>
    <time_frame>13-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of days analgesic (pain) medication was used over the 13 week treatment period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>1 levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets</intervention_name>
    <description>1 tablet daily by mouth</description>
    <arm_group_label>1 levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablet</arm_group_label>
    <other_name>Seasonique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>1 tablet daily by mouth</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sexually na√Øve and agree to abstain from sex during the study

          -  Moderate to severe menstrual-related pelvic pain

          -  Regular spontaneous menstrual cycles

        Exclusion Criteria:

          -  Any contraindication to the use of oral contraceptives

          -  Treatment with an oral contraceptive within the previous 3 months

          -  Previous treatment failure with an extended oral contraceptive regimen
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218-1088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Cincinatti</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 21, 2015</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <firstreceived_results_date>October 12, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cyclic pelvic pain</keyword>
  <keyword>dysmenorrhea</keyword>
  <keyword>oral contraceptives</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dysmenorrhea</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 123 subjects were screened, of which 96 subjects were randomized. Of those randomized, 95 subjects took at lease 1 dose of study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Seasonique</title>
          <description>Seasonique
, 1 tablet daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, 1 tablet daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Pregnant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Seasonique</title>
          <description>Seasonique
, 1 tablet daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, 1 tablet daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
                <measurement group_id="B2" value="48"/>
                <measurement group_id="B3" value="95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15.5" spread="1.23"/>
                <measurement group_id="B2" value="15.4" spread="1.36"/>
                <measurement group_id="B3" value="15.5" spread="1.29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
                <measurement group_id="B2" value="48"/>
                <measurement group_id="B3" value="95"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>African-American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="56"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24.8" spread="6.88"/>
                <measurement group_id="B2" value="26.4" spread="7.16"/>
                <measurement group_id="B3" value="25.6" spread="7.04"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Average Severity for Abdominal/Pelvic Pain</title>
        <description>Defined as the sum of pain scores divided by the total number of days in which the subject experienced abdominal/pelvic pain, from baseline to Week 13 The severity of the pain was assessed using a 4-points scale (0 = ‚ÄúNone‚Äù, 1 = ‚ÄúMild‚Äù, 2 = ‚ÄúModerate‚Äù, 3 = ‚ÄúSevere‚Äù)</description>
        <time_frame>Baseline to end of 13-week treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Complete Cohort: consisted of all randomized subjects who completed the full term of study participation (13 weeks) and who had no recorded protocol violations that would have excluded the from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Seasonique</title>
            <description>Seasonique
, 1 tablet daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 1 tablet daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change in Average Severity for Abdominal/Pelvic Pain</title>
            <description>Defined as the sum of pain scores divided by the total number of days in which the subject experienced abdominal/pelvic pain, from baseline to Week 13 The severity of the pain was assessed using a 4-points scale (0 = ‚ÄúNone‚Äù, 1 = ‚ÄúMild‚Äù, 2 = ‚ÄúModerate‚Äù, 3 = ‚ÄúSevere‚Äù)</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.45" spread="0.060"/>
                  <measurement group_id="O2" value="-0.19" spread="0.058"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Severity of Abdominal/Pelvic Pain</title>
        <description>Maximum pain severity score was calculated by identifying each subject's maximum recorded pain severity from baseline to end of Week 13.
The severity of the pain was assessed using a 4-points scale (0 = ‚ÄúNone‚Äù, 1 = ‚ÄúMild‚Äù, 2 = ‚ÄúModerate‚Äù, 3 = ‚ÄúSevere‚Äù)</description>
        <time_frame>Baseline to end of Week 13</time_frame>
        <safety_issue>No</safety_issue>
        <population>Complete Cohort: consisted of all randomized subjects who completed the full term of study participation (13 weeks) and who had no recorded protocol violations that would have excluded the from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Seasonique</title>
            <description>Seasonique
, 1 tablet daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 1 tablet daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Severity of Abdominal/Pelvic Pain</title>
            <description>Maximum pain severity score was calculated by identifying each subject's maximum recorded pain severity from baseline to end of Week 13.
The severity of the pain was assessed using a 4-points scale (0 = ‚ÄúNone‚Äù, 1 = ‚ÄúMild‚Äù, 2 = ‚ÄúModerate‚Äù, 3 = ‚ÄúSevere‚Äù)</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.62" spread="0.120"/>
                  <measurement group_id="O2" value="-0.17" spread="0.117"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Menstrual Bleeding and /or Spotting</title>
        <time_frame>Baseline to end of Week 13</time_frame>
        <safety_issue>No</safety_issue>
        <population>Complete Cohort: consisted of all randomized subjects who completed the full term of study participation (13 weeks) and who had no recorded protocol violations that would have excluded the from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Seasonique</title>
            <description>Seasonique, 1 tablet daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 1 tablet daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Menstrual Bleeding and /or Spotting</title>
            <units>Days of bleeding/spotting over 13 weeks</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28.389" spread="14.705"/>
                  <measurement group_id="O2" value="18.000" spread="6.026"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Missed From School/Work or Other Activities</title>
        <time_frame>13-week treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Complete Cohort: consisted of all randomized subjects who completed the full term of study participation (13 weeks) and who had no recorded protocol violations that would have excluded the from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Seasonique</title>
            <description>Seasonique
, 1 tablet daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 1 tablet daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Days Missed From School/Work or Other Activities</title>
            <units>Days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.83" spread="1.844"/>
                  <measurement group_id="O2" value="2.75" spread="3.418"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analgesic Use</title>
        <description>number of days analgesic (pain) medication was used over the 13 week treatment period</description>
        <time_frame>13-week treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Complete Cohort: consisted of all randomized subjects who completed the full term of study participation (13 weeks) and who had no recorded protocol violations that would have excluded the from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Seasonique</title>
            <description>Seasonique, 1 tablet daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 1 tablet daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Analgesic Use</title>
            <description>number of days analgesic (pain) medication was used over the 13 week treatment period</description>
            <units>Days analgsic was used over 13 weeks</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.92" spread="3.281"/>
                  <measurement group_id="O2" value="4.03" spread="5.356"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Seasonique</title>
          <description>Seasonique
, 1 tablet daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, 1 tablet daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation of Stress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Excruciating pain rlated to menstruation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can (i) review results communications prior to public release and can embargo communications regarding trial results for a period of at least 60 days but no more than 180 days from the time submitted to the sponsor for review; and (ii) require in instances of a multi-center study, that a single PI not disclose study data until after the multi-center results are published, provided such results are published within eighteen (18) months of the conclusion of the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Duramed Research Protocol Chair</name_or_title>
      <organization>Duramed Research</organization>
      <phone>215-293-7279</phone>
      <email>role_medical_affairs@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
